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Abstract: - This study aimed to assess the knowledge, attitude, and practices on the use of hydroxychloroquine on COVID-19 
patients among physicians in government tertiary hospitals as well as to provide a list of currently administered drugs, vitamins or 
therapy to COVID-19 patients in order to alleviate the symptoms caused by SARS-CoV-2. It involved 100 licensed physicians 
working in a government tertiary hospital in the Philippines. An online survey was utilized for the informed consent and 
questionnaire. The respondents were screened in order to confirm if they fit the inclusion criteria. The respondents were assessed 
based on their demographic profile and knowledge, attitude, and practice towards the use of hydroxychloroquine on COVID-19 
patients. In addition, the respondents were also asked about other drugs that had been prescribed or administered aside from 
hydroxychloroquine. Majority (42%) of the respondents belonged to the 26-30 age group, 54% were male, 28% specialized in 
internal medicine and 91% dealt with COVID-19 patients. The survey revealed that the overall weighted mean in terms of the 
knowledge of the respondents towards the use of hydroxychloroquine on COVID-19 patients was 3.14 which implies that the 
respondents have a moderate knowledge on the use of hydroxychloroquine. There were no significant differences on the knowledge 
of physicians when group according to sex, age and whether they have dealt with COVID-19 patients; moreover, the computed p-
values are .720, .984, and .246 respectively. On the other hand, there was a significant difference in the knowledge of physicians 
when group according to specialization (p = 0.035). The overall weighted mean of the attitude of the respondents was 2.20 implies 
a negative attitude towards the use of hydroxychloroquine but the respondents are interested in reading journal articles and/or cases 
that tackles the use and effects of hydroxychloroquine on COVID-19 patients. The attitude of the respondents were not significantly 
different when grouped according to sex (p = 0.945), age groups (p = 0.554), specialization (p = 0.181) and whether they have dealt 
with COVID-19 patients (p = 0.874). The overall weighted mean of practices was 2.23 which implies disagreement on the use of 
hydroxychloroquine. There were no significant differences on the practices of physicians when grouped according to sex (p = 0.999), 
age groups (p = 0.958), and whether they have dealt with COVID-19 patients (p = 0.588), whereas there was a significant difference 
when grouped according to specialization (p = 0.006). The other drugs prescribed or administered in response to COVID-19 are 
remdesivir and azithromycin. To conclude, the knowledge of the respondents on the new living guidelines by the World Health 
Organization directly influenced the attitude and practices of the physicians and other drugs that can be effectively used in response 
to COVID-19 should be further investigated. 




Coronavirus disease 2019 or the COVID-19 is an infectious 
disease caused by Severe Acute Respiratory Syndrome 
Coronavirus 2 (SARS-CoV-2) that is often compared to a flu 
but the difference is that it attacks the host’s body differently. 
This disease is under the coronavirus group which can be 
structurally characterized by the presence of spike proteins 
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along the lipid envelope, enclosing viral RNA. It is transmitted 
through respiratory droplets from coughing and sneezing and 
contact with the mouth, eyes, or nose with contaminated hands. 
With the rapidly increasing morbidity and mortality of COVID-
19, finding interventions for the disease becomes a global 
priority. Even with the presence of a vaccine, vaccination hasn’t 
become an option in some countries which warrants a 
temporary solution to help the general public long enough for 
immunization options to become available in their respective 
countries [14]. The objective of this study is to come to a 
consensus on the utilization of hydroxychloroquine in 
government tertiary hospitals based on the responses of 
physicians on the use of hydroxychloroquine on COVID-19 
patients. 
Up to the present moment, there is no cure for COVID-19. 
Thus, the scientific community is actively exploring antiviral 
drugs and vaccines for the disease. To interrupt the spread of 
this virus, it relies both on the pharmacologic and 
nonpharmacologic interventions. Social distancing and proper 
hygiene are the habits that help in slowing down the spread of 
viruses among individuals. However, the foremost vital 
medicine interventions to stop SARS-CoV-2 infection should 
be vaccines, and an established medication for short-run 
prophylaxis is another. There are some specific antiviral drugs 
against COVID-19 that are already approved but the problem is 
it is still lacking that is why there are other drugs that are being 
explored [25].  
This study provided a statistically relevant assessment of the 
responses of multiple healthcare workers, primarily physicians 
from government tertiary hospitals, on the utilization of 
hydroxychloroquine in hospitals. The assessment of this study 
is deemed to aid and assist researchers in their clinical research, 
as they discover different treatments to the COVID-19 patients. 
In the early period of the pandemic, hydroxychloroquine and 
chloroquine have been eyed as a potential therapeutic option for 
patients that have COVID-19. Some publications have been 
examining these drugs for further evidence that will support 
their use in patients having COVID-19. Hydroxychloroquine is 
specifically used to prevent and treat malaria. Likewise, this 
drug is used to treat lupus and rheumatoid arthritis which are 
auto-immune diseases. Hydroxychloroquine belongs to a 
category of disease-modifying antirheumatic drugs (DMARDs) 
which can prevent swelling/ache in arthritis and reduce pores 
and skin problems in lupus [21]. Both hydroxychloroquine and 
chloroquine share similar mechanisms of action which increase 
pH within intracellular vacuoles and alter processes such as 
protein degradation by acidic hydrolases in the lysosome, 
assembly of macromolecules in the endosomes, and post 
translational modification of proteins in the Golgi apparatus. 
Using the in vitro, hydroxychloroquine shows to restrict the 
replication of SARS-CoV-2 [10]. 
 According to the study done by Meyerowitz et al. (2020) [19] 
the impact of hydroxychloroquine on cytokine production and 
suppression of antigen presentation may have immunologic 
consequences that hamper innate and adaptive antiviral 
immune responses for patients with COVID-19. There is an 
increasing number of COVID-19 patients that are treated with 
hydroxychloroquine and chloroquine which means that more 
data are gathered. However, there is still no significant clinical 
data that exhibit a clear benefit from the agents used.  
In in vitro results, both hydroxychloroquine and chloroquine 
showed favorable results, still, its data in performance in in vivo 
studies have not been relevant. Most of the data in clinical trials 
that propose both hydroxychloroquine and chloroquine have 
benefits to COVID-19 patients are still in their preliminary 
stages. In addition, there were ongoing trials that have been 
canceled and the reason is not yet clear if it is due to the adverse 
effects of the drugs or its unsuccessful results [12].  
There is increasing data about the use of hydroxychloroquine in 
COVID-19 patients, however, there is no evidence in the 
improvement of patients infected with COVID-19 using the 
randomized controlled trials or any single therapy of 
hydroxychloroquine. For the prophylaxis, post exposure 
prophylaxis, and treatment of hydroxychloroquine in patients 
with COVID-19, it is still under observation [18]. 
II. METHODOLOGY 
  A. Research Design  
 
A descriptive-normative study was conducted in government 
tertiary hospitals. The researchers gathered data and assessed 
the knowledge, attitude, and practices of health workers 
specifically licensed physicians on the use of 
hydroxychloroquine on COVID-19 patients. In addition, 
demographic data was obtained in order to categorize the health 
workers based on their demographic profile. 
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  B. Subjects and Study Site 
 
The subjects of the study are the physicians working in 
government tertiary hospitals in the Philippines. In this study, 
the researchers were able to gather 114 respondents. However, 
14 physicians were disqualified since two of them did not 
consent to participate, seven of them are not working in a 
government hospital, and five of them weren’t able to answer 
whether they are currently working in a government tertiary 
hospital. Thus, in total, the data was derived from 100 
physicians from tertiary government hospitals in the 
Philippines. The sample size complied with a 10% margin of 
error, 95% confidence level, and response distribution of 50% 
computed on the Roasoft calculator. The participants of this 
study were determined by implementing a purposive and 
convenience sampling technique for the purpose to effectively 
select representative samples. The study has been conducted 
throughout the academic year 2020-2021, at which the survey 
questionnaire was deployed to the respondents during the 
month of April of 2021 until May of 2021 through google 
forms. Participants were also given the liberty to withdraw from 
the study at any time. 
 
Table.1.Inclusion and exclusion criteria 
 
Inclusion Criteria  Exclusion Criteria  
● Licensed 
physicians in the 
Philippines 
 
● Age group ranging 




employed in a 
government 
tertiary hospital  
● Other licensed 
health workers  
 




  C. Data Measure/Instrumentation 
 
The researchers utilized a questionnaire drawn out based on the 
previous studies reported in the review of related literature. This 
was divided into four categories which consist of demographic 
profile, knowledge, attitude, and practices of the respondents. 
Each part (knowledge, attitude, and practices) was used to 
address the objectives of the study, overall the questionnaire 
contained 25 questions. The questionnaire was formulated 
through Google forms, an online tool used for research surveys. 
The survey questionnaires were disseminated via email and 
social media platforms such as Facebook, Twitter, Instagram, 
Messenger, Viber and Telegram which allow researchers to 
have easier access and communication in the data collection. 
Participants were physicians from the government tertiary 
hospitals.  
 
The researchers utilized Cronbach’s alpha to measure the 
reliability of a set of scales or the set of survey questions for 
validation before distributing the questionnaires to the 
participating physicians on the use of hydroxychloroquine on 
COVID-19 Patients. Cronbach’s alpha is a measure on a test’s 
internal consistency to ensure that said test is indeed reliable 
and valid enough to be given out [27].  
  
Table.2. Reliability Test using Cronbach’s Alpha  
Cronbach’s 
Alpha 
                    N of items 
.913                                          25 
 
The validity index using Cronbach’s alpha was computed to be 
.913.  
 
In the collection of data, the researchers sent a request to 
participate in the study to the physician. An informed consent 
was given out for the respondents and was fully informed first 
regarding the subjects of the study before answering the survey 
provided by the researchers. The researchers respected the 
decision of every respondent on whether or not to get involved 
with the research. The respondents were given a choice to 
indicate their name or remain anonymous to consider privacy 
of information. The information gathered was held confidential 
and only be dislodged to the research team alone. The findings 
of the study were available to the respondents once the study 
was completed.   
 
  D. Data Gathering Procedure 
 
The data gathering procedure of this study utilized an online 
survey questionnaire through Google Forms due to the 
constraints brought by the COVID-19 pandemic. The online 
survey consisted of five parts; informed consent, demographics, 
knowledge, attitude, and practice. The demographic profile 
included the specialty of the physician and those who 
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responded with their subspecialties are included under their 
generalized specialties. Under the knowledge part, it included 
Chemical Structure and Pharmacokinetics of 
hydroxychloroquine, Benefits and Side Effects of 
hydroxychloroquine, Administration, Dosage, and Storage of 
hydroxychloroquine. For the attitude part, Interest and Opinion 
towards hydroxychloroquine and Inclination on prescription 
was included. Based on the limitations of the study, the criteria 
of respondents were licensed physicians from government 
tertiary hospitals were the coverage of this study. 
 
The qualified respondents were asked for their informed 
consent before proceeding to the online survey questionnaire in 
accordance with standard ethical practice. In the informed 
consent, it included general details on the intent of the study 
and provided a substantial discussion of participants' rights, 
such as the right to privacy and confidentiality, the right to 
withdraw from the study, and the right to ask questions and to 
raise any concerns. After the completion of surveys, using the 
Google Forms application, survey results were compiled and 
were statistically analyzed. 
 
 
Fig.1. Data Gathering Procedure Flowchart 
 
  E. Ethical Considerations 
 
In the study conducted, ethical considerations served as 
guidelines in fulfilling the truthfulness, knowledge and 
adherence of error in misinterpreting the data acquired. Ethical 
considerations entailed protection for both of the researchers 
and participants of the study. Furthermore, the researchers 
declared no conflict of interest along the course of study. The 
study protocol was approved by the Tondo Medical Center 
Research Ethics Committee and the Faculty of Pharmacy 
Research Ethics Committee. 
In the collection of data, an informed consent was given out for 
the respondents and they were fully informed first regarding the 
subjects of the study prior to answering the survey provided by 
the researchers. The researchers respected the decision of every 
respondent on whether or not to get involved with the research. 
The respondents had given a choice to indicate their name or 
remain anonymous to consider privacy of information. The 
information that had been gathered were held as confidential 
and only be dislodged to the research team alone. The findings 
of the study will be available to the respondents once the study 
is completed. 
  
  F. Data Analysis 
 
The analysis of data is necessary for proving the statistical 
significance of the data collected. The study aimed to describe 
the knowledge, attitude, and practices of physicians on the use 
of hydroxychloroquine on COVID-19 patients in tertiary 
government hospitals. A minimum of 100 total participants 
were needed based on an online sample size calculator from 
Rasoft inc. The survey was conducted through the use of 
Google forms and informed consent was required prior to 
starting the survey. To describe the data, the study used 
frequency count and weighted mean and interpreted the data 
using the following scale and verbal interpretation: 
 
Table.3. Scale and Verbal Interpretation 
Scale Verbal Interpretation 
4.20 – 5.00 Strongly Agree 
3.40 – 4.19 Agree 
2.60 – 3.39 Neutral 
1.80 – 2.59 Disagree 
1.0    – 1.79 Strongly Disagree 
 
Note: The verbal interpretation for the assessment of 
knowledge is very highly knowledgeable, highly 
knowledgeable, moderately knowledgeable, somewhat 
knowledgeable, and not knowledgeable. 
To determine the significance of the knowledge, attitudes, and 
practices of physicians on the use of hydroxychloroquine on 
COVID-19 patients in government tertiary hospitals when 
grouped according to their demographic profile, analysis of 
variance (ANOVA) testing was used. ANOVA testing is a 
method that is used to separate variances in order to determine 
what effect the independent variable has [11]. 
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III. RESULTS AND DISCUSSION 
   A. Description of the Profile of the Respondents  
 
The profile of the respondents was described using their age, 
sex, specialization, and whether they have dealt with or have 
been dealing with covid-19 patients. 
 
Table.4 presents the description of the respondents as to their 
age, specialization, and whether they have dealt with or have 
been dealing with Covid-19 patients. 
 
Table.4. Description Of The Respondents as to their Age, Sex, 
Specialization, and Whether They Have Dealt With Or Have Been 
Dealing With Covid-19 Patients. 
Demographic Profile f % 
        Age 
26 – 30 
31 – 35 
36 – 40 
41 – 45 












































































 Dealing or Having dealt with COVID-19 Patients 






As to Age: 
 
Table 4 showed that almost half (42%) belongs to the 26-30 age 
group and 38% belongs to the 31-35 age group. According to 
the recent research brief by the University of the Philippines 
Population Institute or UPPI and Demographic Research and 
Development Foundation, Inc. or DRDF (2020) [29], sixty-five 
percent of health professionals are under the age of 35.  
 
As to Sex: 
 
Table 4 depicts that the majority of the respondents were male 
(54%) but based on the UPPI and DRDF (2020) the majority of 
the health professionals are females.  
 
As to Specialization: 
 
Based on Table 4, most of the respondents (28%) belonged to 
internal medicine as their specialization which has a very huge 
part in the ongoing pandemic. According to Johnson S.B., & 
Butcher F. (2020) [15], all of the medical doctors have a duty 
and limitations in handling patients especially during the 
pandemic since the degree of obligation varies between 
specialties within certain constraints.  
 
As to dealing/ having dealt with COVID-19 patients: 
Based on Table 4, 91% of the respondents are dealing or have 
dealt with COVID-19 patients since not all licensed physicians 
or specializations deal with patients diagnosed with COVID-19 
and according to Johnson S.B., & Butcher F. (2020) [15] opting 
out of medical doctors is justifiable during the pandemic if it 
extends beyond their area of expertise.  
Description of the Knowledge of Physicians on the Use of 
Hydroxychloroquine on COVID-19 patients  
Table.5. delineates the knowledge of physicians on the use of 
hydroxychloroquine on COVID-19 patients. 
 
Table.5. Knowledge of Physicians on the Use of Hydroxychloroquine 
on COVID-19 Patients 
 
Parameter WM VI 
Chemical Structure and 
Pharmacokinetics of 
Hydroxychloroquine 
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belongs to the antiviral 






Benefits and Side Effects of 
Hydroxychloroquine 
3. Hydroxychloroquine can 
reduce the viral load of 
SARS-CoV-2. 
2.21 SK 
4. Hydroxychloroquine can 
cause adverse cardiac 
effects. 
4.12 HK 
Administration, Dosage, and 
Storage Hydroxychloroquine 
5. Hydroxychloroquine is 
orally administered. 
4.44  VHK 
6. The specific dose for 
Hydroxychloroquine in 
administering to COVID-19 
patients is 400 mg once a day 




7. Hydroxychloroquine can be 
administered with or without 
azithromycin. 
2.85 MK 
8. Hydroxychloroquine is 
stored at room temperature 
up to 25°C. 
2.7  MK 
9. As of December 17, 2020, 
strong recommendation 
against the use of 
hydroxychloroquine in 
patients with COVID-19 






Overall WM 3.14 MK 
Note. VHK - Very Highly Knowledgeable, HK - Highly 
Knowledgeable, MK - Moderately Knowledgeable, SK - Somewhat 
Knowledgeable 
Overall, as can be gleaned from Table 5 the overall weighted 
mean of 3.14 implies that the physicians have moderate 
knowledge on the use of hydroxychloroquine. The Table 5 
shows that respondents had highest knowledge that the drug 
hydroxychloroquine is orally administered with a 4.4 weighted 
mean while the respondents had lowest knowledge that 
hydroxychloroquine can reduce the viral load of SARS-CoV-2 
with 2.21 weighted mean. According to Morrisette et al., (2020) 
[20], hydroxychloroquine is orally given as a sulfate which is 
then absorbed in the upper intestinal tract. Faíco-Filho et al. 
(2020) [9] found no difference in viral load reduction among 
samples of patients using the same time score as other studies 
that looked at viral load clearance in different clinical 
presentations and concluded that there was no difference in 
viral load in vivo when hydroxychloroquine was used in non-
critical hospitalized patients with COVID-19. Based on the 
website of World Health Organization on the Coronavirus 
disease (COVID-19) advice for the public updated last May 5, 
2021 [33], hydroxychloroquine is being studied as a possible 
treatment for COVID-19 but according to current data, this drug 
does not reduce deaths among COVID-19 patients in hospitals, 
nor does it help people with moderate disease. 
Description of the Attitude of Physicians on the Use of 
Hydroxychloroquine on COVID-19 patients  
 
Table 6 presents the attitude of physicians on the use of 
hydroxychloroquine on COVID-19 patients. 
 
Table.6. Attitude of Physicians on the Use of Hydroxychloroquine on 
COVID-19 Patients 
Parameter WM VI 
Interest towards Hydroxychloroquine 
1. I am interested in reading 
journal articles and/or case 
reports about 
Hydroxychloroquine and its 




    
2. I think Hydroxychloroquine is 
safe.  
2.96 N 
3. I am convinced of its antiviral 
effects.  
2.34 D 
4. I am in favor of its use as 
prophylaxis for contacts or 
frontline health workers 
1.70 SD 
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Inclination to its prescription 
5. I would recommend 
Hydroxychloroquine to a 
relative with COVID-19 if 
under the circumstances.  
1.69 SD 
6. I would personally take 
Hydroxychloroquine as 
medication for COVID-19 if 
under the circumstances.   
1.62 SD 
7. I would prescribe 
Hydroxychloroquine on 
patients with mild symptoms.  
1.49 SD 
Overall WM 2.20 SD 
Note. A - Agree, N - Neutral, D - Disagree, SD - Strongly Disagree 
 
Overall, as can be gleaned from Table 6 the overall weighted 
mean of 2.20 implies that the physicians believed that the use 
of hydroxychloroquine is still questionable and concrete 
evidence is needed. Aforementioned from Table 6, it is 
highlighted that a calculated mean of 3.58 from the respondents 
are willing to educate themselves supported by reliable 
resources upon the mechanism of the drug hydroxychloroquine 
in terms of COVID-19 treatment intervention. Abassi et al. 
(2020) [1] claimed that hydroxychloroquine/chloroquine are 
capable of affecting several cellular pathways and therefore 
may have several mechanisms of action against SARS-CoV-2 
but additional studies examining hydroxychloroquine and 
chloroquine in preventing and treating COVID-19 are 
desperately needed. Additionally, based from the table above, 
it is deduced that the physicians highly regard 
hydroxychloroquine as safe to administer. Hydroxychloroquine 
nonetheless has a 65-year track record of safety when 
prescribed at recommended doses in populations with normal 
liver and kidney function and without preexisting cardiac 
arrhythmias [4]. U.S. Food and Drug Administration [32] 
cautions against use of hydroxychloroquine or chloroquine for 
COVID-19 outside of the hospital setting or a clinical trial due 
to risk of heart rhythm problems. In response to the question 
whether the physicians would prescribe hydroxychloroquine on 
patients with mild symptoms, a weighted mean of 1.49 has been 
found implying that physicians think that hydroxychloroquine 
has little impact in curing mild symptoms of COVID-19. 
Statement stated by the WHO (2021), clinical trials confirm that 
hydroxychloroquine does not prevent illness or death of 
COVID-19. Moreover, Bull et al., (2020) [5] of CDC mandated 
that in prescribing hydroxychloroquine, patient’s complete 
medical and medication must be presented to evaluate risks by 
the nonroutine prescribers of  hydroxychloroquine.   
 
Description of the Practices of Physicians on the Use of 
Hydroxychloroquine on COVID-19 patients  
 
Table.7. illustrates the practices of physicians on the use of 
hydroxychloroquine on COVID-19 patients. 
 
Table.7. Practices of Physicians on the Use of Hydroxychloroquine on 
COVID-19 Patients 
Parameter WM VI 
1. At one point in time, 
Hydroxychloroquine 
was one prescribed to 
COVID-19 patients as 
a practice.  
2.65 N 
2. As a practice, 
Hydroxychloroquine is 
currently prescribed to 
COVID-19 patients.  
1.55 SD 
3. As a practice, 
Hydroxychloroquine is 
prescribed at 400 mg 
once a day for about 5-
15 days. 
2.07 D 
4. As a practice, 
Hydroxychloroquine is 
stored at room 
temperature up to 25°C 
before administration. 
2.68 N 
5. As a practice, there are 
existing policies in the 






6. In line with the 
announcement of 
COVID-19 vaccines in 
the Philippines, 
changes were made in 
the guidelines of the 
hospital on the use of 
Hydroxychloroquine.  
2.98 N 
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7. I have taken 
Hydroxychloroquine 
as prophylaxis for 
COVID-19 
1.16 SD 
8. Patients will lose their 




Overall WM 2.23 D 
Note. A - Agree, N - Neutral, D - Disagree, SD - Strongly Disagree 
Based on Table.7, the overall weighted mean of 2.23 implies 
that the physicians disagree when it comes to the use of 
hydroxychloroquine on COVID-19 Patients. The respondents 
were neutral when changes were made in the guidelines of the 
hospital on the use of hydroxychloroquine when the 
announcement of COVID-19 vaccines in the Philippines were 
made which have the highest weighted mean of 2.98. The 
respondents disagree that they have taken hydroxychloroquine 
as prophylaxis for COVID-19 with the lowest mean of 1.16. 
Based on the systematic review of Smit et al. (2021) [24] on the 
prophylaxis used for COVID-19, a number of COVID-19 
prophylactic candidates are currently being tested in clinical 
trials in a variety of countries and settings. However, data from 
completed studies and randomized controlled trials, appear to 
indicate that hydroxychloroquine is ineffective. Public advisory 
by the Philippine College of Surgeons was also posted on their 
website on the use of hydroxychloroquine stating that patients 
who have not been confirmed positive for COVID-19 or who 
are otherwise healthy and want to avoid infection should not 
take these drugs. It also added that hydroxychloroquine or 
chloroquine taken incorrectly can cause vision loss. 
Overall, the knowledge of physicians on the use of 
hydroxychloroquine on COVID-19 patients has the highest 
weighted mean compared to their attitude and practices. 
According to the latest guidelines of World Health 
Organization updated last December 2020, regardless of illness 
severity of COVID-19 in patients, they strongly do not 
recommend the use of hydroxychloroquine. It suggests that 
hydroxychloroquine is unlikely to minimize mortality or the 
need for mechanical ventilation, and they may not even shorten 
hospitalizations. In addition, there is further evidence that using 
hydroxychloroquine on COVID-19 patients increases the risk 
of diarrhea and nausea/vomiting. Furthermore, it also reviewed 
the use of hydroxychloroquine alone or with azithromycin and 
there was no indication that adding azithromycin to 
hydroxychloroquine changed its effect on any result.  
Test of Significant Differences on the Knowledge of Physicians 
on the Use of Hydroxychloroquine on COVID-19 Patients when 
grouped according to their profile  
 
Table.8. displays the test of significant differences on the 
knowledge of physicians on the use of hydroxychloroquine on 
COVID-19 patients when grouped according to their profile. 
 
Table.8. Test of Significant Differences on the Knowledge of 
Physicians on the Use of Hydroxychloroquine on COVID-19 Patients 









Sex .133 .720 NS 
Age .134 .984 NS 
Specialization 1.98 .035 S 
Treated 
COVID-19 
patient or not 
1.453 .246 NS 
Note.  NS - Not Significant, S - Significant 
Table.8. exhibits the F-test results of the test of significant 
differences on the knowledge of physicians on the use of 
hydroxychloroquine on COVID-19 patients when grouped 
according to their profile. The computed p-values of .720, .984, 
.246 for sex, age, and whether they have treated COVID-19 
patients, respectively are all greater than. Hence, there is 
enough statistical evidence to accept the null hypothesis and 
conclude that there is no significant difference on the 
knowledge of physicians on the use of hydroxychloroquine on 
COVID-19 patients when grouped according to their sex, age, 
and whether they have treated COVID-19 patients at 5% level 
of significance. 
On the other hand, the computed p-value of .035 is less than. 
Hence, there is enough statistical evidence to reject the null 
hypothesis and conclude that there is a significant difference in 
the knowledge of physicians on the use of hydroxychloroquine 
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on COVID-19 patients when grouped according to their 
specialization. 
Studies have shown that specialization plays a major role in 
terms of prescribing medication to patients. This is due to the 
fact that each specialization has different knowledge and 
competencies towards patient care. In terms of managing 
certain diseases such as COVID-19, studies have shown that 
internal medicine has the highest percentage in dealing with 
infectious disease patients compared to other specialties as they 
have greater skills or experience (Baptista et al., 2020). 
However, Abou-Abbas et al. (2020) [3] presented that there is 
no significant difference in the knowledge of physicians when 
grouped according to their specialization. It was only noted that 
physicians with an experience of 10 years and above are more 
likely to have good knowledge and practices on COVID-19.   
Test of Significant Differences on the Attitude of Physicians on 
the Use of Hydroxychloroquine on COVID-19 Patients when 
grouped according to their profile  
 
Table.9. shows the statistical values on the differences on the 
attitude of physicians on the use of hydroxychloroquine on 
COVID-19 patients based on demographic profile  
Table.9. Significant Differences on the Attitude of Physicians on the 








Sex 0.005 0.945 NS 
Age 0.805 0.554 NS 
Specialization 1.377 0.181 NS 
Treated 
COVID-19 
Patient or not 
0.026 0.874 NS 
Note.  NS - Not Significant, S - Significant 
Table.9. shows the F-test results of the test of significant 
difference on the attitudes of physicians on the use of 
hydroxychloroquine on COVID-19 patients when grouped 
according to their profile. The computed p-values of .945, .554, 
.181, and .874 for sex, age, specialization and whether they 
have treated COVID-19 patients, respectively are all greater 
than. Hence, there is enough statistical evidence to accept the 
null hypothesis and conclude that there is no significant 
difference on the attitudes of physicians on the use of 
hydroxychloroquine on COVID-19 patients when grouped 
according to their profile at 5% level of significance. 
 
Although there have been studies that state that there is a 
significant difference in the attitudes of physicians with 
different demographic profiles, such as the one made by 
Demour et al. (2020) [8] and Sürmelioğlu et al. (2020) [26]. 
According to Demour (2020) [8], there were significant 
differences in the attitudes of physicians with different 
professional degrees as well as age. The differences were seen 
in age groups with large gaps such as those between 22-35 years 
old and 36-50 years old. This can be due to the fact that older 
physicians tend to have more experience in dealing with 
different situations than younger physicians hence the 
difference in attitudes. It is important to note that although this 
study does look at the demographic profile of physicians and 
their attitudes towards COVID-19 and its treatments, it doesn’t 
discuss too much on the attitudes on the use of 
hydroxychloroquine.   
 
Test of Significant Differences on the Practices of Physicians 
on the Use of Hydroxychloroquine on COVID-19 Patients when 
grouped according to their profile  
 
Table.10. presents the statistical values on the differences on 
the practices of physicians on the use of hydroxychloroquine on 
COVID-19 patients based on demographic profile. 
Table.10. Test of Significant Differences on the Practices of 
Physicians on the Use of Hydroxychloroquine on COVID-19 Patients 






Sex 0.000 0.999 NS 
Age 0.207 0.958 NS 
Specialization 2.392 0.006 S 
Treated 
COVID-19 
Patient or not 
0.307 0.588 NS 
Note.  NS - Not Significant, S - Significant 
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Table.10. shows the F-test results of the test of significant 
difference on the practices of physicians on the use of 
hydroxychloroquine on covid-19 patients when grouped 
according to their profile. The computed p-values of .999, .958, 
.588 for sex, age, and whether they have treated COVID-19 
patients, respectively are all greater than 𝑎 = 0.05. Hence, 
there is enough statistical evidence to accept the null hypothesis 
and conclude that there is no significant difference on the 
practices of physician on the use of hydroxychloroquine on 
covid-19 patients when grouped according to their sex, age, and 
whether they have treated COVID-19 patients at 5% level of 
significance. 
 
On the other hand, the computed p-value of .006 is less than 
𝑎 = 0.05.Hence, there is enough statistical evidence to reject 
the null hypothesis and conclude that there is a significant 
difference in the practices of physicians on the use of 
hydroxychloroquine on covid-19 patients when grouped 
according to their specialization.  
According to the study of Davari et.al. (2018) [7], the attributes 
of the physicians including their specialty, clinical experience, 
and their continuous professional development and practice 
decision were among the prescriber related factors that are 
commonly mentioned. The article also shows that the influence 
of the specialist physicians could greatly affect their prescribing 
decisions. Specialist physicians influence the drug prescription 
especially on more complex conditions and on patients that 
have more specific disease like autoimmune disease and 
infectious disease. Almost all of the general practitioners, in 
terms of prescribing new medicine, depend on the advice of the 
specialists. 
Description of Other Drugs, Vitamins, or Therapy Prescribed 
or Administered by Physicians in Response to Covid-19  
 
Table.11. reveals the description of other 
drug/s/vitamins/therapy prescribed or administered by 
physicians in response to COVID-19. 
 
Table.11. Description of other Drug/s/Vitamins/Therapy Prescribed or 
Administered by Physicians in response to COVID-19 
 
Drug/Vitamins/Therapy  f Rank 
Chloroquine 2 10 
Remdesivir 73 1.5 
Lopinavir-ritonavir 5 8 
Favipiravir (Avigan) 17 6 
Oseltamivir (Tamiflu) 14 7 
Azithromycin 73 1.5 
Vitamin C (Ascorbic Acid) 65 3 
Corticosteroids 52 4 
Sirolimus 2 10 
Tocilizumab 49 5 
Anakinra 2 10 
Hemoperfusion  1 15.5 
Cefuroxime 1 15.5 
Ceftriaxone 1 15.5 
Meropenem 1 15.5 
Enoxaparin 1 15.5 
Multivitamins + Zinc 1 15.5 
INTERNATIONAL JOURNAL OF PROGRESSIVE RESEARCH IN SCIENCE AND ENGINEERING, VOL.2, NO.8, AUGUST 2021. 
 
  
AUSTIN MATHEW V. CHAN., et.al: KNOWLEDGE, ATTITUDE, AND PRACTICES ON THE USE OF HYDROXYCHLOROQUINE 
ON COVID-19 PATIENTS AMONG PHYSICIANS IN GOVERNMENT TERTIARY HOSPITALS 
296 
 
Cefixime 1 15.5 
Lianhua Qingwen 1 15.5 
None 13 8 
 
Table.11. Shows the list and the ranking of other 
drugs/vitamins/therapy prescribed or administered by the 
physicians in response to COVID-19 wherein drugs that tied 
were ranked based on their computed mean. Thus, 1.5th place 
serves as the highest ranking since 2 drugs tied for the first spot 
while 15.5th place serves as the lowest ranking since the 12th 
up to the 19th spot tied. The list includes various 
pharmacological agents and such as antiviral agents 
(chloroquine, remdesivir, lopinavir-ritonavir, favipiravir, and 
oseltamivir), supporting agents (azithromycin, vitamin C, 
corticosteroids, sirolimus, tocilizumab, and anakinra), and 
traditional herbal medicine such the Linhua Qingwen, which 
are all mentioned in a 2020 article [35]. Other drugs 
(enoxaparin, cefuroxime, ceftriaxone, meropenem, 
multivitamins + zinc, cefixime, and hemoperfusion) are also 
included in the list, which can also be observed to place last on 
the ranking along with Linhua Qingwen. Some physicians also 
opted to prescribe none to COVID-19 patients.  
 
According to the data gathered, it can be observed that 
remdesivir and azithromycin were equally deemed to be the 
most prescribed by physicians. This supports the claim of 
Sanders et al. [23] in 2020 stating that remdesivir is perceived 
to be the most promising therapy in combating COVID-19 
symptoms. National Institutes of Health (NIH) in October 2020 
[30] also reported remdesivir as an effective treatment for they 
have shown a quicker recovery period of an average of 10 days 
compared to that of 15 days observed from other treatments. 
Azithromycin, on the other hand, was described to not only 
have antiviral activity but also conduct immunomodulatory 
effects as well [6]. Moreover, azithromycin is also reported by 
studies that they perform synergistically along with other 
antiviral agents such as hydroxychloroquine [16]; [22].   
On the ranking, remdesivir and azithromycin are then followed 
by vitamin C, corticosteroid, and tocilizumab, respectively. 
According to Abobaker et al. [2], vitamin C plays a role in 
managing COVID-19 as it provides nutrition support for the 
body that is safe and shows no major side effects [34]. Though 
corticosteroid ranked 4th, it is currently not recommended by 
few journals [28]; [23] and is considered non beneficial to both 
severe and critical COVID-19 patients [34]. However, in an 
NIH issuance [31], corticosteroids such as dexamethasone were 
strongly recommended particularly for COVID-19 patients 
with respiratory conditions since improvements on patients 
were observed.  Lastly, the obtained result on tocilizumab 
supports the consistent reports regarding its safety and 
effectiveness in improving symptoms derived from COVID-19 
especially to patients requiring respiratory support [13].  
As for Lianhua Qingwen, which is considered as traditional 
Chinese medicine, although its use has been prevalent in China 
and has shown favorable results with its antiviral, anti-
inflammatory, and immunoregulatory effects in COVID-19 
patients [17], it is still ranked as one of the least prescribed by 
the physicians. This might be in accordance with an April 2021 
DOH issuance regarding the initial banning of Lianhua 
Qingwen, wherein it was clarified that Lianhua Qingwen is only 
registered in FDA in the Philippines as traditional herbal 
medicine and not as a medication for COVID-19.  
IV. CONCLUSION 
  A. Profile of the Respondents 
Based on the respondent’s profile, most of them are within the 
26 - 30 year old bracket, which is the age norm of healthcare 
professionals taking residency training or have specialization. 
Meanwhile, the majority of the respondents were male. Results 
also show that most of the physicians belong to internal 
medicine followed by surgery which evidently show that 
specialization influences medication prescription to COVID-19 
patients as they are more knowledgeable in handling infectious 
disease. Furthermore, most of the respondents are dealing with 
COVID-19 patients since almost all licensed physicians opt to 
handle patients even if it is not included in their area of 
specialization.  
Knowledge of Physicians on the Use of Hydroxychloroquine on 
COVID-19 patients  
  
The total number of physicians with specializations has 
moderate knowledge on the use of hydroxychloroquine as a 
pharmacologic therapy for COVID-19 patients.  The 
respondents revealed that the drug’s route of administration is 
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oral, and it’s mechanism of action, having the lowest 
knowledge from the participants, can reduce the viral load of 
SARS-COV-2. 
 
Attitude of Physicians on the Use of Hydroxychloroquine on 
COVID-19 patients  
The use of hydroxychloroquine as a medical treatment for 
COVID-19 patients is still questionable. Most of the 
respondents are willing to read journal articles and/or case 
reports about the drug’s mechanism of action towards COVID-
19. However, some of them are not willing to give 
hydroxychloroquine but would rather choose drugs such 
remdesivir, azithromycin, vitamin C, corticosteroid, and 
tocilizumab as the drug of choice. Studies have shown that the 
use of hydroxychloroquine is no longer recommended 
regardless of the severity of the disease as it may show side 
effects in patients such as diarrhea, nausea or vomiting and eye 
damage when given in high doses. 
Practices of Physicians on the Use of Hydroxychloroquine on 
COVID-19 patients  
Most of the physicians are neutral when it comes to the use of 
hydroxychloroquine on patients due to the change of guidelines 
for the treatment of COVID-19. Moreover, new studies have 
shown that the use of hydroxychloroquine is revealed to be 
ineffective in the treatment of COVID-19 and if taken 
incorrectly will have side effects such as vision loss. 
Knowledge of Physicians on the Use of Hydroxychloroquine on 
COVID-19 Patients when grouped according to their profile  
The study reveals that physicians’ profiling based on their 
specialization contributes to how much they know about the use 
of hydroxychloroquine as a pharmacologic aid in treating 
COVID-19 patients. This is because different medical 
specializations deal with distinct branches of the medical field, 
as a result, physicians under certain specializations such as 
internal medicine are more knowledgeable and familiar with 
medicine prescriptions to COVID-19 cases compared to others.   
Attitude of Physicians on the Use of Hydroxychloroquine on 
COVID-19 Patients when grouped according to their profile  
With the gathered result, it can be concluded that the 
demographic profile of physicians did not play a role in the 
attitude of physicians towards the use of hydroxychloroquine 
on COVID-19 patients. Physicians’ age, sex, specialization, 
and whether they have treated COVID-19 patients were all 
negligible in how they view hydroxychloroquine as a COVID-
19 regimen.    
Practices of Physicians on the Use of Hydroxychloroquine on 
COVID-19 Patients when grouped according to their profile  
The obtained result suggests that the practice of physicians on 
the use of hydroxychloroquine on COVID-19 patients is 
notably influenced by their specific medical specialization for 
the reason that certain specialties are more experienced in 
handling COVID-19 cases while other specializations are rarely 
exposed to this type of case.   
Other drugs, vitamins, or therapy prescribed or administered 
by physicians in response to COVID-19  
  
COVID-19 regimen may vary depending on the severity of the 
symptoms. Nevertheless, drugs that are mostly prescribed by 
physicians working in tertiary government hospitals in the 
Philippines were remdesivir, azithromycin, vitamin C, 
corticosteroid, and tocilizumab mostly due to the sufficient 
evidence of their effectiveness and safety when administered to 
COVID-19 patients. The effectiveness and adverse effects of 
the listed plausible treatments to manage COVID-19 are also 
constantly updated, as a result, the use of some drugs, such as 
hydroxychloroquine, are being discontinued to be prescribed to 
COVID-19 patients. However, there are still a number of other 
therapies being administered by physicians and some are under 
clinical trials to help combat the symptoms derived from 
COVID-19.  
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